Apyx Medical (APYX) Liabilities and Shareholders Equity (2010 - 2026)

Apyx Medical (APYX) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $63.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 4.76% year-over-year to $63.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $245.4 million (down 2.27% YoY) and the FY2025 annual result came in at $66.8 million, up 3.08% from the prior year.
• Liabilities and Shareholders Equity fell to $63.0 million in Q1 2026, from $66.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $79.2 million in Q4 2023 to a low of $51.8 million in Q4 2022.
• A 5-year average of $62.0 million and a median of $60.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity retreated 24.66% — and 2023, when it soared 53.05%.
• Tracing APYX's Liabilities and Shareholders Equity over 5 years: stood at $51.8 million in 2022, then soared by 53.05% to $79.2 million in 2023, then slipped by 18.17% to $64.8 million in 2024, then increased by 3.08% to $66.8 million in 2025, then slipped by 5.71% to $63.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $63.0 million (Q1 2026), $66.8 million (Q4 2025), and $57.4 million (Q3 2025), per Business Quant data.